Sign inJoin waitlistJoin the waitlist

UV

Ulka Vaishampayan

Physician · University of Michigan Health-Ann Arbor

Credentials: · · ·

History

University of Michigan Health-Ann Arbor
2020–Present

Medical Oncology
1996–1998
Internal Medicine
1993–1996
Doctor of Medicine
1989–1993

Research

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
The Lancet · 2017 · 1,812 citations
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Journal of Clinical Oncology · 2015 · 901 citations
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
The Lancet Oncology · 2013 · 828 citations

Sumanta Pal
54 papers
Neeraj Agarwal
48 papers
Toni Choueiri
43 papers
DH
Daniel Heng
30 papers
Sandy Srinivas
30 papers
Matthew Galsky
28 papers
Maha Hussain
27 papers
EH
Elisabeth Heath
26 papers
LH
Lauren Harshman
26 papers
Evan Yu
24 papers
JR
Jonathan Rosenberg
24 papers
Joaquim Bellmunt
23 papers

Clinical trials

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
Principal investigator · Recruiting · Phase 1, Phase 2
University of Michigan Rogel Cancer Center
2025–2031
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Principal investigator · Active not recruiting · Phase 2
University of Michigan Rogel Cancer Center
2021–2027
Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo
Principal investigator · Completed · Phase 2
Barbara Ann Karmanos Cancer Institute
2018–2023
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Principal investigator · Completed
Barbara Ann Karmanos Cancer Institute
2013–2019